Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library

Antibiotics

Hongxia Niu¹  Peng Cui¹  Wanliang Shi¹  Shuo Zhang¹  Jie Feng¹  Yong Wang²  David Sullivan¹  Wenhong Zhang³  Bingdong Zhu⁴  Ying Zhang¹ 

[1] Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA; E-Mails:;Department of Clinical Microbiology Lab, Provincial Hospital Affiliated to Shandong University, Jinan 250021, China; E-Mail:;Key Laboratory of Medical Molecular Virology, Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China; E-Mail:;Lanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China; E-Mail:

关键词: Escherichia coli;    persisters;    anti-persister activity;    clinical drug library;    urinary tract infection;   

DOI  :  10.3390/antibiotics4020179

来源: mdpi

【 摘 要 】

Uropathogenic E. coli is a major cause of urinary tract infections (UTIs), but current antibiotics do not always effectively clear the persistent infection. To identify drugs that eliminate uropathogenic E. coli persisters, we screened a clinical drug library consisting of 1524 compounds using high throughput drug exposure assay in 96-well plates. Bacterial survival was assessed by growth on LB plates. We identified 14 drug candidates (tosufloxacin, colistin, sparfloxacin, moxifloxacin and gatifloxacin, enrofloxacin and sarafloxacin, octodrine, clofoctol, dibekacin, cephalosporin C, pazufloxacin, streptomycin and neomycin), which had high anti-persister activity. Among them, tosufloxacin and colistin had the highest anti-persister activity and could completely eradicate E. coli persisters in 3 days in vitro while the current UTI antibiotics failed to do so. Our findings may have implications for the development of a more effective treatment for UTIs.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.